Description

Mirapex PD Tablets with Prolonged Release 0.375 mg. №30

Ingredients

Each tablet contains 0.375 mg of pramipexole dihydrochloride monohydrate as the active ingredient.

Dosage

The recommended dosage is determined by a healthcare professional based on individual needs. It is typically taken once daily, with or without food. Do not crush or chew the tablets; swallow them whole with a full glass of water.

Indications

Mirapex PD tablets are indicated for the treatment of Parkinson’s disease. They help improve muscle control and reduce stiffness, allowing for better movement and coordination.

Contraindications

Do not use Mirapex PD tablets if you are allergic to pramipexole or any other ingredients in the formulation. Patients with a history of impulse control disorders should use this medication with caution.

Directions

Follow the instructions provided by your healthcare provider for the best results. Take the medication at the same time each day to maintain a consistent level in your body. Do not stop taking Mirapex PD suddenly without consulting your doctor.

Scientific Evidence

Studies have shown that pramipexole, the active ingredient in Mirapex PD tablets, effectively improves motor symptoms in patients with Parkinson’s disease. Research published in the Journal of Neurology indicates that pramipexole has a favorable safety profile and is well-tolerated by most patients.

Additional Information

It is important to report any unusual side effects or changes in behavior to your healthcare provider while taking Mirapex PD tablets. Regular follow-up appointments are necessary to monitor the medication’s effectiveness and adjust the dosage if needed.

Mirapex PD tablets with prolonged release 0.375 mg. №30 provide a sustained release of pramipexole, a dopamine agonist that acts on dopamine receptors in the brain. By stimulating these receptors, pramipexole helps restore the balance of dopamine, a neurotransmitter involved in movement control. This mechanism of action results in improved muscle coordination and reduced symptoms of Parkinson’s disease.

Clinical trials have demonstrated the efficacy of Mirapex PD tablets in managing both early and advanced stages of Parkinson’s disease. A study published in the Journal of Parkinson’s Disease found that pramipexole significantly reduced motor complications and improved quality of life in patients with advanced Parkinson’s disease compared to placebo. These findings highlight the importance of early intervention with pramipexole to optimize treatment outcomes.